VimRx, Baxter deal

The companies signed a letter of intent to form a joint venture in ex vivo cell and gene therapy that will combine the assets of Baxter's Immunotherapy Division (Irvine, Calif.), including the Isolex 300 magnetic-cell separation system, with VMRX's genomics technology. ...